Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Current Medicinal Chemistry

PROTACs Targeting Molecular Targets in Triple-Negative Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

GKGyas KhanSASarfaraz AhmadMHMd Sadique Hussain

Discussion

Loading...

Member takes

Overview

Review highlights PROTACs targeting key proteins in triple-negative breast cancer, suggesting improved drug efficacy.

Key Points

  • PROTACs effectively degrade oncoproteins, overcoming drug resistance in triple-negative breast cancer.
  • Key targets include BET proteins, PARP1, and c-Myc, showing promise in reducing cancer progression.
  • Challenges remain in enhancing pharmacokinetics and preventing toxicity during treatment.
  • Recent developments in PROTAC design could lead to more effective therapies for triple-negative breast cancer patients.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477d0b6https://doi.org/10.2174/0109298673384371250806104406
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Translational Research on the Oral Delivery of the Cytotoxic PROTAC Molecule via Tumor-Targeting Prodrug Strategy for Triple-Negative Breast Cancer Treatment.2025
  2. 2Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies2025 · 5 citations
  3. 3Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation2025 · 5 citations
  4. 4Triple-Negative Breast Cancer: Molecular Subtypes, Therapeutic Challenges, and Emerging Strategies—A Systematic Review2025
  5. 5Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities2025